Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer

Dworakowska, Dorota; Góźdż, Stanisław; Jassem, Ewa; Badzio, A.; Kobierska, G; Urbaniak, Anna; Skokowski, Jan; Damps, I; Jassem, Jacek

doi:10.1016/s0169-5002(01)00287-2

Cited by 35 publications

(23 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have suggested that PCNA represents an unfavorable prognostic factor [38,39]. However, PCNA expression was not correlated with prognosis in the current study, in accordance with results of other authors [40,41].…”

Section: Discussionsupporting

confidence: 91%

Prognostic impact of nm23‐H1 and PCNA expression in pathologic stage I non‐small cell lung cancer

Liu

Wang

et al. 2011

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Prognostic impact of nm23‐H1 and PCNA expression in pathologic stage I non‐small cell lung cancer

Liu

Wang

et al. 2011

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…p53 overexpression as well as p53 mutational status alone had no significant influence on survival. This result, a weak prognostic significance of p53 alterations in lung cancer, is in concordance with findings of other groups [22,23]. When adding the information about the expression status of p53 to the nuclear expression status of YB-1, however, the dichotomy of the negative prognostic relevance of nuclear YB-1 expression becomes even more striking.…”

Section: Discussionsupporting

confidence: 87%

Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer

Geßner¹,

Woischwill²,

Schumacher³

et al. 2004

European Respiratory Journal

View full text Add to dashboard Cite

The human Y-box binding protein, YB-1, is a multifunctional protein that regulates gene expression. Nuclear expression of YB-1 has been associated with chemoresistance and poor prognosis of tumour patients.Representative samples from autopsied material of primary tumours from 77 patients with NSCLC were investigated by immunohistochemistry for subcellular distribution of YB-1 and p53, in order to evaluate the prognostic role of nuclear expression of YB-1.Cytoplasmic YB-1 expression was found in all tumour samples, whereas nuclear expression was only observed in 48%. There was no correlation with histological classification, clinical parameters or tumour size, stage and metastasis status. However, patients with positive nuclear YB-1 expression in tumours showed reduced survival times when compared with patients without nuclear expression. Including information about the histology and mutational status for p53 increased the prognostic value of nuclear YB-1. Patients with nuclear YB-1 expression and p53 mutations had the worst prognosis (median survival 3 months), while best outcome was found in patients with no nuclear YB-1 and wildtype p53 (median survival 15 months).This suggests that the combined analysis of both markers allows a better identification of subgroups with varying prognosis. Nuclear expression of Y-box binding protien seems to be an independent prognostic marker.

show abstract

“…The prognostic value of P53 mutations and expression is questionable [38]. In our earlier studies, we did not demonstrate a prognostic relevance of these alterations, however different tumor samples were then used [39,40]. Results of the present study could suggest that MDM2 alterations may characterize better than P53 gene mutations a more aggressive subgroup of NSCLC.…”

Section: Mdm2 Amplification and Prognosismentioning

confidence: 49%

MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC)

Dworakowska¹,

Jassem²,

Jassem³

et al. 2004

Lung Cancer

View full text Add to dashboard Cite

Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer

Cited by 35 publications

References 19 publications

Prognostic impact of nm23‐H1 and PCNA expression in pathologic stage I non‐small cell lung cancer

Prognostic impact of nm23‐H1 and PCNA expression in pathologic stage I non‐small cell lung cancer

Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer

MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC)

Contact Info

Product

Resources

About